Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57,259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Zhang P, et al. Among authors: huang j. Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209298 Clinical Trial.
Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z, Zheng Y, Cao W, Zhang Y, Zhao Z, Wang G, Zhao J, Cai S, Shao X, Huang J, Ye W, Huang Y, Li W, Huang X, Wu H, Wang X, Yin Y. Chen Z, et al. Among authors: huang x, huang j, huang y. Cancer Med. 2019 Sep;8(12):5544-5553. doi: 10.1002/cam4.2460. Epub 2019 Aug 6. Cancer Med. 2019. PMID: 31385461 Free PMC article.
Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Huang J, Huang P, Shao XY, Sun Y, Lei L, Lou CJ, Ye WW, Chen JQ, Cao WM, Huang Y, Zheng YB, Wang XJ, Chen ZH. Huang J, et al. Among authors: huang p, huang y. Medicine (Baltimore). 2020 Jul 17;99(29):e20821. doi: 10.1097/MD.0000000000020821. Medicine (Baltimore). 2020. PMID: 32702824 Free PMC article.
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Zhang J, et al. Among authors: huang j. Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827. Clin Cancer Res. 2022. PMID: 34844975 Clinical Trial.
Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z, Ouyang Q, Wang Y, Wang J, Wang H, Wu X, Zhang P, Huang J, Zheng Y, Cao W, Shao X, Xie N, Tian C, Liang H, Wang C, Zhang Y, Ren D, Wang X. Chen Z, et al. Among authors: huang j. Front Oncol. 2022 Mar 3;12:829693. doi: 10.3389/fonc.2022.829693. eCollection 2022. Front Oncol. 2022. PMID: 35311126 Free PMC article.
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Among authors: huang j. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
57,259 results
You have reached the last available page of results. Please see the User Guide for more information.